Hospital Reimbursement Price Cap for Cancer Drugs: The French Experience in Controlling Hospital Drug Expenditures

Autor: C. Rieu, M. Angalakuditi, M. Bensadon, C. Le Pen, P Paubel, Albane Degrassat-Théas

Publikováno v: PharmacoEconomics
PharmacoEconomics, 2012, 30 (7), 〈10.2165/11588320-000000000-00000〉
PharmacoEconomics, 2012, 30 (7), ⟨10.2165/11588320-000000000-00000⟩

Background:Background: In 2005, the French Government implemented a new way of financing high-cost drugs for hospitals in order to promote innovation. Such drugs are gathered on a positive list, established by the Ministry of Health, with a reimburse

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdbf504dd2fb10e1e56e3acf4ab153c3
http://PharmacoEconomics.adisonline.com/pt/re/pec/pdfhandler.00019053-201230070-00003.pdf